I85PREP
⌘ K
Facharzt FMH Medizinische Onkologie - independent subject foundations study materials
Facharzt FMH Medizinische Onkologie - independent subject foundations study resources

Facharzt FMH Medizinische Onkologie - independent subject foundations practice questions

One question at a time. Build your Facharzt FMH Medizinische Onkologie - independent subject foundations understanding.

First 50 of 190 questions. Each one lists the choices, the correct answer, and an explanation. The checker at the top of this page saves progress in this browser when it is available.

Continue in the practice tool above to load more questions, 50 at a time.

Question 1Solid tumors: site, stage, biology and treatment intent

A 49-year-old woman with metastatic HER2-positive (IHC 3+) invasive ductal breast cancer experiences disease progression in the liver and lungs while receiving first-line maintenance trastuzumab and pertuzumab following induction docetaxel. She is asymptomatic with an ECOG performance status of 0 and normal baseline left ventricular ejection fraction (LVEF 60%). Based on ESMO guidelines and the DESTINY-Breast03 trial, what is the standard second-line systemic therapy of choice?

  1. Trastuzumab emtansine (T-DM1) monotherapy
  2. Trastuzumab deruxtecan (T-DXd) Correct answer.
  3. Lapatinib plus capecitabine
  4. Tucatinib plus trastuzumab and capecitabine

Explanation

Trastuzumab deruxtecan (T-DXd) is the standard second-line therapy for metastatic HER2-positive breast cancer following progression on a taxane and dual HER2 blockade. In the randomized Phase III DESTINY-Breast03 trial, T-DXd demonstrated dramatic superiority over T-DM1 in progression-free survival (HR 0.28) and overall survival, establishing it as the preferred second-line treatment.

Question 2Solid tumors: site, stage, biology and treatment intent

A 42-year-old premenopausal woman is diagnosed with clinical stage IIB (cT2 cN1 M0) triple-negative breast cancer (TNBC). Genetic testing is negative for germline BRCA1/2 mutations. In accordance with the KEYNOTE-522 trial and ESMO guidelines, what is the standard neoadjuvant and adjuvant treatment paradigm?

  1. Neoadjuvant dose-dense AC followed by paclitaxel alone, followed by definitive surgery and adjuvant capecitabine for 8 cycles
  2. Neoadjuvant carboplatin plus paclitaxel followed by surgery, omitting anthracyclines and adjuvant therapy if a pathologic complete response is attained
  3. Neoadjuvant pembrolizumab monotherapy for 6 months followed by surgery and observation
  4. Neoadjuvant pembrolizumab combined with carboplatin/paclitaxel followed by doxorubicin/cyclophosphamide, then definitive surgery, followed by adjuvant pembrolizumab to complete 1 year Correct answer.

Explanation

The KEYNOTE-522 regimen is the international standard of care for high-risk early triple-negative breast cancer (stage II/III). It consists of neoadjuvant pembrolizumab plus platinum-containing chemotherapy (carboplatin plus paclitaxel followed by doxorubicin or epirubicin plus cyclophosphamide), followed by definitive breast surgery and continued adjuvant pembrolizumab for up to 9 cycles (totaling approximately 1 year of immunotherapy), significantly improving pathologic complete response (pCR) and event-free survival regardless of pCR status.

Question 3Solid tumors: site, stage, biology and treatment intent

A 38-year-old woman with a documented deleterious germline BRCA1 mutation completes neoadjuvant anthracycline/taxane chemotherapy and bilateral mastectomy for triple-negative breast cancer. Final surgical pathology reveals residual invasive carcinoma measuring 1.8 cm with 1 positive axillary lymph node (ypT1c ypN1a, non-pCR). Which adjuvant targeted therapy is indicated based on the Phase III OlympiA trial to improve invasive disease-free and overall survival?

  1. Adjuvant Olaparib orally for 1 year Correct answer.
  2. Adjuvant Talazoparib orally for 6 months
  3. Adjuvant Niraparib combined with bevacizumab for 2 years
  4. Adjuvant Rucaparib monotherapy for 3 years

Explanation

The OlympiA Phase III trial demonstrated that 1 year of adjuvant olaparib (a PARP inhibitor) significantly improves invasive disease-free survival (IDFS) and overall survival (OS) in patients with high-risk, HER2-negative early breast cancer harboring germline BRCA1 or BRCA2 mutations who have residual disease after neoadjuvant chemotherapy (or high-risk features upfront).

Question 4Solid tumors: site, stage, biology and treatment intent

A 44-year-old premenopausal woman is diagnosed with de novo metastatic ER-positive (90%), PR-positive (70%), HER2-negative breast cancer with multiple non-visceral bone metastases. She has no visceral crisis. What constitutes the standard first-line systemic management according to SGMO and ESMO guidelines?

  1. Tamoxifen monotherapy without ovarian ablation to avoid premature menopausal symptoms
  2. Ovarian function suppression (GnRH agonist or bilateral oophorectomy) combined with an aromatase inhibitor (or fulvestrant) and a CDK4/6 inhibitor (e.g., ribociclib) Correct answer.
  3. Single-agent capecitabine until disease progression followed by second-line endocrine therapy
  4. Doxorubicin plus cyclophosphamide (AC) chemotherapy followed by maintenance fulvestrant

Explanation

Premenopausal women with ER+/HER2- metastatic breast cancer without visceral crisis should receive endocrine therapy plus a CDK4/6 inhibitor (such as ribociclib, which demonstrated an overall survival benefit in MONALEESA-7) combined with ovarian function suppression (OFS via GnRH agonists like goserelin/leuprolide or surgical oophorectomy) to render them postmenopausal, enabling effective aromatase inhibition or fulvestrant therapy.

Question 5Solid tumors: site, stage, biology and treatment intent

A 58-year-old non-smoking man undergoes complete surgical resection (lobectomy and systematic mediastinal lymphadenectomy) for stage IIA (pT2b pN0 M0) non-small cell lung cancer (adenocarcinoma). Molecular pathology confirms an EGFR exon 19 deletion. He completes 4 cycles of adjuvant cisplatin plus vinorelbine. Based on the Phase III ADAURA trial, what is the next standard step in his curative management?

  1. Observation with routine chest CT surveillance every 6 months
  2. Adjuvant erlotinib for 1 year
  3. Adjuvant osimertinib (80 mg orally daily) for up to 3 years Correct answer.
  4. Adjuvant thoracic radiotherapy followed by durvalumab

Explanation

In the Phase III ADAURA trial, adjuvant osimertinib (80 mg daily for up to 3 years) demonstrated a profound disease-free survival benefit and a statistically significant overall survival benefit (HR 0.49) in patients with completely resected stage IB–IIIA EGFR-mutated (exon 19 deletion or L858R) NSCLC following standard adjuvant chemotherapy.

Question 6Solid tumors: site, stage, biology and treatment intent

A 64-year-old woman is newly diagnosed with metastatic lung adenocarcinoma with extensive bone and pleural metastases. Next-generation sequencing (NGS) reveals an EGFR exon 21 L858R point mutation. She has no neurologic symptoms and an ECOG performance status of 1. According to the FLAURA and FLAURA2 trials and ESMO guidelines, what represents standard first-line systemic management?

  1. Afatinib monotherapy until progression followed by osimertinib
  2. Cisplatin plus pemetrexed doublet chemotherapy alone
  3. Pembrolizumab plus carboplatin and pemetrexed
  4. Osimertinib monotherapy (or osimertinib combined with platinum-pemetrexed chemotherapy) Correct answer.

Explanation

Third-generation EGFR TKI osimertinib is the standard first-line treatment for EGFR-mutated (exon 19 del / L858R) advanced NSCLC based on the FLAURA trial, which showed superior progression-free survival, overall survival, and central nervous system (CNS) efficacy compared to first-generation TKIs. Furthermore, FLAURA2 demonstrated that adding platinum-pemetrexed chemotherapy to osimertinib further extends progression-free survival.

Question 7Solid tumors: site, stage, biology and treatment intent

A 48-year-old non-smoker presents with stage IV lung adenocarcinoma with asymptomatic brain metastases. Molecular profiling confirms an EML4-ALK fusion rearrangement (ALK-positive). PD-L1 expression is 85%. Which first-line systemic therapy provides the highest central nervous system penetration and superior progression-free survival according to ESMO guidelines?

  1. Second- or third-generation ALK TKI (such as Alectinib, Brigatinib, or Lorlatinib) Correct answer.
  2. Pembrolizumab monotherapy based on high PD-L1 expression (TPS ≥ 50%)
  3. Crizotinib monotherapy with whole-brain radiotherapy
  4. Carboplatin plus paclitaxel and bevacizumab

Explanation

Next-generation ALK tyrosine kinase inhibitors (such as alectinib, brigatinib, or lorlatinib) are the preferred first-line standard of care for ALK-rearranged NSCLC. The Phase III ALEX and CROWN trials demonstrated marked superiority of next-generation TKIs over crizotinib, achieving median progression-free survivals exceeding 30–38+ months and exceptional intracranial activity, effectively controlling and preventing brain metastases without upfront whole-brain radiation.

Question 8Solid tumors: site, stage, biology and treatment intent

A 66-year-old man with a 40 pack-year smoking history is diagnosed with metastatic non-squamous non-small cell lung cancer (cT3 cN2 cM1c with adrenal and contralateral lung lesions). Comprehensive genomic profiling reveals no actionable mutations in EGFR, ALK, ROS1, BRAF, RET, MET, or KRAS. Immunohistochemistry for PD-L1 shows a Tumor Proportion Score (TPS) of 0%. His ECOG performance status is 1 and renal function is normal. What is the standard first-line treatment regimen?

  1. Docetaxel monotherapy
  2. Platinum doublet chemotherapy (cisplatin or carboplatin plus pemetrexed) combined with Pembrolizumab (or Nivolumab plus Ipilimumab plus 2 cycles of chemotherapy) Correct answer.
  3. Pembrolizumab monotherapy
  4. Osimertinib combined with bevacizumab

Explanation

For patients with metastatic non-squamous NSCLC without actionable genomic alterations and PD-L1 TPS < 1% (or 0%), standard first-line therapy is platinum-pemetrexed chemotherapy combined with pembrolizumab (KEYNOTE-189) or dual checkpoint inhibition with nivolumab plus ipilimumab and 2 cycles of platinum doublet chemotherapy (CheckMate 9LA). Both strategies demonstrate significant overall survival superiority over platinum doublet chemotherapy alone.

Question 9Solid tumors: site, stage, biology and treatment intent

A 71-year-old former smoker presents with stage IV squamous non-small cell lung cancer with extensive mediastinal lymphadenopathy and bone metastases. Tumor genomic testing is negative for actionable driver alterations, and PD-L1 immunohistochemistry shows a Tumor Proportion Score (TPS) of 80%. His ECOG performance status is 1. Which first-line treatment strategy is supported by the KEYNOTE-024 and EMPOWER-Lung 1 trials as a standard chemotherapy-free option?

  1. Gefitinib monotherapy
  2. Cisplatin plus gemcitabine chemotherapy alone
  3. Anti-PD-1 monotherapy with Pembrolizumab (or Cemiplimab / Atezolizumab) Correct answer.
  4. Ipilimumab monotherapy

Explanation

In patients with advanced NSCLC lacking actionable oncogenic drivers and expressing high PD-L1 levels (TPS ≥ 50%), frontline anti-PD-1 monotherapy (pembrolizumab per KEYNOTE-024/042 or cemiplimab per EMPOWER-Lung 1) or anti-PD-L1 monotherapy (atezolizumab per IMpower110) provides significant overall survival benefits, prolonged durations of response, and a favorable toxicity profile compared to platinum-based chemotherapy.

Question 10Solid tumors: site, stage, biology and treatment intent

A 65-year-old male with metastatic non-small cell lung adenocarcinoma experiences disease progression after 14 months on first-line carboplatin, pemetrexed, and pembrolizumab. NGS panel testing confirms the presence of a KRAS p.G12C mutation. Which targeted therapeutic agent is specifically indicated for this molecular alteration following prior systemic chemo-immunotherapy?

  1. Osimertinib
  2. Dabrafenib plus trametinib
  3. Capmatinib
  4. Sotorasib (or Adagrasib) Correct answer.

Explanation

Sotorasib and adagrasib are small-molecule covalent inhibitors that specifically bind to the switch II pocket of mutant KRAS G12C in its inactive GDP-bound state, locking it in an inactive conformation. They are approved for patients with KRAS G12C-mutated locally advanced or metastatic NSCLC who have received at least one prior systemic therapy.

Question 11Solid tumors: site, stage, biology and treatment intent

A 60-year-old man completes definitive concurrent chemoradiotherapy (cisplatin/etoposide with 60 Gy thoracic radiation) for unresectable stage IIIA (cT3 cN2 M0) lung adenocarcinoma. Repeat contrast-enhanced CT of the chest and abdomen 4 weeks post-radiation demonstrates a partial response with no evidence of progressive disease or radiation pneumonitis. According to the Phase III PACIFIC trial, what is the standard consolidation therapy?

  1. Durvalumab (anti-PD-L1 antibody) every 2 or 4 weeks for up to 12 months Correct answer.
  2. Adjuvant platinum-based chemotherapy for an additional 4 cycles
  3. Consolidation nivolumab plus ipilimumab for 2 years
  4. Prophylactic cranial irradiation (PCI) followed by clinical observation

Explanation

The Phase III PACIFIC trial established 12 months of consolidation durvalumab (an anti-PD-L1 monoclonal antibody) as the global standard of care for patients with unresectable stage III NSCLC whose disease has not progressed following definitive concurrent platinum-based chemoradiotherapy. Durvalumab demonstrated statistically significant and clinically robust improvements in both progression-free survival and 5-year overall survival.

Question 12Solid tumors: site, stage, biology and treatment intent

A 63-year-old heavy smoker is diagnosed with extensive-stage small cell lung cancer (ES-SCLC) with symptomatic mediastinal compression and multiple hepatic metastases. What is the standard first-line systemic regimen recommended by ESMO and SGMO guidelines based on the IMpower133 and CASPIAN trials?

  1. Cisplatin plus irinotecan alone without immunotherapy
  2. Platinum (carboplatin or cisplatin) plus etoposide combined with an anti-PD-L1 antibody (Atezolizumab or Durvalumab) Correct answer.
  3. Topotecan monotherapy with prophylactic cranial irradiation
  4. Cyclophosphamide, doxorubicin, and vincristine (CAV) alternating with etoposide/cisplatin

Explanation

Based on the landmark Phase III IMpower133 and CASPIAN trials, the standard first-line therapy for extensive-stage small cell lung cancer (ES-SCLC) is 4 cycles of platinum-etoposide chemotherapy (carboplatin or cisplatin plus etoposide) combined with an anti-PD-L1 checkpoint inhibitor (either atezolizumab or durvalumab), followed by maintenance anti-PD-L1 monotherapy until disease progression.

Question 13Solid tumors: site, stage, biology and treatment intent

A 61-year-old woman is diagnosed with de novo metastatic colorectal cancer with bilobar liver metastases. Molecular pathology of the primary biopsy reveals a KRAS codon 12 mutation (exon 2 p.G12D) and proficient mismatch repair (MSS). Why are anti-EGFR monoclonal antibodies (such as cetuximab and panitumumab) strictly contraindicated in her systemic treatment regimen?

  1. KRAS mutations cause immediate severe hypersensitivity reactions to monoclonal antibody infusions
  2. Anti-EGFR antibodies downregulate EGFR expression, triggering transformation into small-cell neuroendocrine carcinoma
  3. KRAS mutations cause rapid hepatic enzymatic degradation of circulating IgG1 antibodies
  4. Mutations in KRAS constitutively activate downstream RAS-RAF-MEK-ERK signaling independently of upstream EGFR blockade, conferring primary resistance and potential harm Correct answer.

Explanation

Activating mutations in KRAS or NRAS (exons 2, 3, and 4) cause constitutive, ligand-independent activation of the downstream MAPK signaling cascade. Upstream blockade of EGFR by cetuximab or panitumumab cannot extinguish this downstream signaling. Multiple randomized Phase III trials (such as PRIME and CRYSTAL) demonstrated that administering anti-EGFR antibodies to patients with RAS-mutant mCRC provides no therapeutic benefit and can accelerate disease progression and worsen survival.

Question 14Solid tumors: site, stage, biology and treatment intent

A 52-year-old woman is diagnosed with synchronous metastatic adenocarcinoma of the descending colon (left-sided primary) with multiple unresectable liver metastases. Extended molecular profiling confirms that the tumor is RAS wild-type (KRAS/NRAS wild-type in exons 2, 3, 4), BRAF V600E wild-type, HER2 non-amplified, and MSS. Her ECOG performance status is 0. According to ESMO guidelines and prospective clinical trials (PARADIGM, CALGB/SWOG 80405), what is the optimal first-line systemic regimen?

  1. Doublet chemotherapy (mFOLFOX6 or FOLFIRI) combined with an anti-EGFR antibody (Cetuximab or Panitumumab) Correct answer.
  2. Single-agent Bevacizumab maintenance therapy
  3. Regorafenib monotherapy
  4. Pembrolizumab plus Lenvatinib

Explanation

In patients with metastatic colorectal cancer whose primary tumor originates on the left side of the colon (from the splenic flexure to the rectum) and is RAS/BRAF wild-type, first-line doublet chemotherapy (mFOLFOX6 or FOLFIRI) combined with an anti-EGFR monoclonal antibody (cetuximab or panitumumab) produces superior objective response rates, higher resection conversion rates, and significantly longer overall survival compared to chemotherapy plus bevacizumab (as proven in the randomized Phase III PARADIGM trial).

Question 15Solid tumors: site, stage, biology and treatment intent

A 59-year-old man with metastatic right-sided colon adenocarcinoma harboring a BRAF p.V600E mutation and proficient mismatch repair (MSS) experiences disease progression on first-line FOLFOX plus bevacizumab. His ECOG performance status is 1. Based on the Phase III BEACON CRC trial, what targeted regimen is the standard second-line therapy?

  1. Ipilimumab plus nivolumab
  2. Encorafenib (BRAF inhibitor) plus Cetuximab (anti-EGFR antibody) Correct answer.
  3. Dabrafenib plus trametinib monotherapy without anti-EGFR antibody
  4. Trastuzumab plus lapatinib

Explanation

In colorectal cancer, BRAF V600E inhibition as monotherapy results in rapid EGFR-mediated feedback reactivation of the MAPK pathway. The Phase III BEACON CRC trial established that combining the BRAF inhibitor encorafenib with the anti-EGFR monoclonal antibody cetuximab significantly improves overall survival, progression-free survival, and objective response rates compared to standard chemotherapy in pretreated BRAF V600E-mutant mCRC.

Question 16Solid tumors: site, stage, biology and treatment intent

A 68-year-old woman is diagnosed with metastatic cecal adenocarcinoma with peritoneal and retroperitoneal nodal metastases. Immunohistochemistry reveals loss of MLH1 and PMS2 nuclear expression, and PCR confirms high microsatellite instability (MSI-H / dMMR). Her ECOG performance status is 1. What is the standard first-line systemic therapy supported by the KEYNOTE-177 and CheckMate 8HW trials?

  1. FOLFOXIRI plus bevacizumab
  2. Capecitabine plus oxaliplatin (CAPOX) alone
  3. Immune checkpoint inhibitor therapy with Pembrolizumab monotherapy (or Nivolumab plus Ipilimumab) Correct answer.
  4. Trifluridine/tipiracil (FTD/TPI)

Explanation

In the Phase III KEYNOTE-177 trial, first-line pembrolizumab monotherapy doubled progression-free survival (median 16.5 vs 8.2 months) and demonstrated superior durability of response with fewer toxicities compared to standard frontline chemotherapy regimens in patients with dMMR/MSI-H metastatic colorectal cancer. Furthermore, CheckMate 8HW demonstrated that first-line nivolumab plus ipilimumab provides even higher progression-free survival benefits over chemotherapy.

Question 17Solid tumors: site, stage, biology and treatment intent

A 64-year-old patient with metastatic colorectal cancer has progressed through all standard therapies including FOLFOX, FOLFIRI, bevacizumab, and (being KRAS wild-type) panitumumab. His ECOG performance status is 1. In the Phase III SUNLIGHT trial, which combination demonstrated a statistically significant overall survival benefit in this refractory setting over single-agent control?

  1. Sorafenib plus capecitabine
  2. Erlotinib plus gemcitabine
  3. Mitomycin C plus 5-FU infusion
  4. Trifluridine/tipiracil (FTD/TPI) plus Bevacizumab Correct answer.

Explanation

The randomized Phase III SUNLIGHT trial demonstrated that adding bevacizumab to trifluridine/tipiracil (FTD/TPI) significantly improved overall survival (median OS 10.8 vs 7.5 months, HR 0.61) and progression-free survival compared to trifluridine/tipiracil monotherapy in patients with refractory metastatic colorectal cancer who had progressed on two prior lines of chemotherapy.

Question 18Solid tumors: site, stage, biology and treatment intent

A 57-year-old man is diagnosed with locally advanced, resectable gastric adenocarcinoma of the antrum (cT3 cN1 cM0, MSS, HER2-negative). He is medically fit with an ECOG performance status of 0. According to the German AIO-FLOT4 trial and ESMO clinical guidelines, what is the standard perioperative treatment regimen?

  1. FLOT regimen (5-Fluorouracil, Leucovorin, Oxaliplatin, Docetaxel) administered for 4 cycles preoperatively followed by surgery and 4 cycles postoperatively Correct answer.
  2. Upfront total gastrectomy with D2 lymphadenectomy followed by 6 months of postoperative adjuvant capecitabine monotherapy
  3. Neoadjuvant cisplatin plus 5-FU for 2 cycles followed by surgery with no postoperative therapy
  4. Definitive chemoradiotherapy with 50.4 Gy plus weekly carboplatin/paclitaxel without surgical resection

Explanation

The randomized Phase III AIO-FLOT4 trial established the FLOT regimen (four 2-week cycles preoperatively and four 2-week cycles postoperatively of 5-FU, leucovorin, oxaliplatin, and docetaxel) as the standard of care for locally advanced resectable gastric and gastroesophageal junction adenocarcinoma (cT2 or higher, or node-positive), demonstrating significant overall survival and disease-free survival superiority over the older ECF/ECX triplet.

Question 19Solid tumors: site, stage, biology and treatment intent

A 62-year-old woman presents with metastatic gastric adenocarcinoma with multiple liver and peritoneal metastases. Diagnostic biopsy confirms HER2 overexpression (IHC 3+) and a PD-L1 Combined Positive Score (CPS) of 5. According to the KEYNOTE-811 trial and updated ESMO guidelines, what represents the preferred first-line systemic therapy?

  1. FOLFOX chemotherapy plus Nivolumab
  2. Platinum/fluoropyrimidine chemotherapy combined with Trastuzumab plus Pembrolizumab Correct answer.
  3. Trastuzumab deruxtecan (T-DXd) monotherapy
  4. Ramucirumab plus Paclitaxel

Explanation

The Phase III KEYNOTE-811 trial demonstrated that adding the anti-PD-1 antibody pembrolizumab to standard first-line trastuzumab plus fluoropyrimidine/platinum chemotherapy significantly increases objective response rates, progression-free survival, and overall survival in patients with untreated HER2-positive, PD-L1-positive (CPS ≥ 1) metastatic gastric or gastroesophageal junction adenocarcinoma.

Question 20Solid tumors: site, stage, biology and treatment intent

A 54-year-old man with no significant past medical history presents with painless jaundice and abdominal pain. Imaging reveals a 3.5 cm mass in the pancreatic body with multiple liver metastases and encasement of the celiac axis. Bilirubin is normalized after biliary stenting. His ECOG performance status is 0. What is the standard first-line chemotherapy regimen providing the longest median overall survival according to the PRODIGE 4/ACCORD 11 and NAPOLI-3 trials?

  1. Gemcitabine monotherapy
  2. Gemcitabine plus erlotinib
  3. Capecitabine plus radiation therapy
  4. mFOLFIRINOX (or NALIRIFOX) Correct answer.

Explanation

In medically fit patients (ECOG PS 0–1, preserved organ function, normal bilirubin) with metastatic pancreatic ductal adenocarcinoma, modified FOLFIRINOX (5-FU, leucovorin, irinotecan, oxaliplatin per PRODIGE 4/ACCORD 11) or NALIRIFOX (liposomal irinotecan, 5-FU/LV, oxaliplatin per NAPOLI-3) is the preferred standard first-line regimen, achieving significantly higher response rates and longer median overall survival (~11.1–11.4 months) compared to gemcitabine-based regimens.

Question 21Solid tumors: site, stage, biology and treatment intent

A 61-year-old man with compensated hepatitis B cirrhosis (Child-Pugh Class A, score 5) is diagnosed with unresectable hepatocellular carcinoma (BCLC Stage C) with portal vein invasion and lung metastases. Esophagogastroduodenoscopy shows no high-risk esophageal varices. What is the standard first-line systemic therapy according to the Phase III IMbrave150 trial and ESMO guidelines?

  1. Atezolizumab (anti-PD-L1) combined with Bevacizumab (anti-VEGF) Correct answer.
  2. Sorafenib monotherapy
  3. Regorafenib monotherapy
  4. Lenvatinib combined with transarterial chemoembolization (TACE)

Explanation

The Phase III IMbrave150 trial established the combination of atezolizumab (anti-PD-L1) plus bevacizumab (anti-VEGF) as the standard first-line therapy for unresectable hepatocellular carcinoma in patients with Child-Pugh A liver function and adequate variceal screening, demonstrating significant overall survival (median 19.2 months) and progression-free survival superiority over sorafenib.

Question 22Solid tumors: site, stage, biology and treatment intent

A 59-year-old woman is diagnosed with locally advanced, unresectable intrahepatic cholangiocarcinoma with regional lymph node involvement. NGS testing shows no FGFR2 fusions or IDH1 mutations. Her ECOG performance status is 0. Based on the Phase III TOPAZ-1 trial, what is the standard first-line systemic regimen?

  1. Gemcitabine plus capecitabine without immunotherapy
  2. Gemcitabine and Cisplatin combined with Durvalumab Correct answer.
  3. FOLFIRI plus Cetuximab
  4. Paclitaxel plus ramucirumab

Explanation

The global Phase III TOPAZ-1 trial established that adding the anti-PD-L1 checkpoint inhibitor durvalumab to standard gemcitabine and cisplatin (GemCis) chemotherapy significantly improves overall survival and progression-free survival in patients with previously untreated advanced biliary tract cancer (cholangiocarcinoma and gallbladder cancer).

Question 23Solid tumors: site, stage, biology and treatment intent

A 65-year-old man presents with de novo metastatic hormone-sensitive prostate cancer (mHSPC). Staging scans show high-volume disease with >6 bone metastases (including ribs, spine, and pelvis) and multiple retroperitoneal lymph nodes. His ECOG performance status is 1. According to the ARASENS and PEACE-1 trials, what constitutes the modern triplet standard of care?

  1. Androgen deprivation therapy (ADT) monotherapy with surgical castration alone
  2. ADT plus bicalutamide for 30 days followed by observation until castration resistance
  3. ADT combined with Docetaxel chemotherapy plus an Androgen Receptor Pathway Inhibitor (Darolutamide or Abiraterone acetate) Correct answer.
  4. Cabazitaxel plus enzalutamide

Explanation

In fit patients with de novo metastatic hormone-sensitive prostate cancer (mHSPC), particularly with high-volume disease, modern Phase III clinical trials (ARASENS and PEACE-1) have demonstrated that triplet therapy combining ADT, docetaxel chemotherapy (6 cycles), and an androgen receptor pathway inhibitor (darolutamide or abiraterone acetate with prednisone) provides profound overall survival benefits compared to ADT plus docetaxel doublet alone.

Question 24Solid tumors: site, stage, biology and treatment intent

A 66-year-old man with metastatic castration-resistant prostate cancer (mCRPC) progresses while receiving abiraterone acetate. Somatic and germline tumor genomic profiling identifies a homozygous deletion of the BRCA2 gene. According to the Phase III PROfound and TRITON3 trials, what targeted therapy is approved and indicated to prolong progression-free and overall survival?

  1. PARP inhibitor therapy (Olaparib or Rucaparib) Correct answer.
  2. Sipuleucel-T autologous cellular immunotherapy
  3. Mitoxantrone plus prednisone
  4. Ipilimumab plus nivolumab

Explanation

In the Phase III PROfound and TRITON3 trials, the PARP inhibitors olaparib and rucaparib demonstrated significant improvements in radiographic progression-free survival and overall survival compared to physician's choice of alternative ARPI (enzalutamide or abiraterone) in patients with mCRPC harboring homologous recombination repair (HRR) gene alterations, with the greatest benefit observed in patients with BRCA1 or BRCA2 alterations.

Question 25Solid tumors: site, stage, biology and treatment intent

A 58-year-old man presents with metastatic clear cell renal cell carcinoma (ccRCC) with multiple lung and bone metastases. Laboratory analysis reveals anemia (hemoglobin 10.2 g/dL), elevated corrected calcium (10.8 mg/dL), and time from diagnosis to systemic therapy < 1 year, classifying him as IMDC intermediate/poor risk. What is the preferred first-line systemic management according to ESMO and SGMO guidelines?

  1. Sunitinib monotherapy
  2. Dual immunotherapy with Ipilimumab plus Nivolumab (or an IO-TKI combination such as Pembrolizumab plus Lenvatinib / Cabozantinib) Correct answer.
  3. High-dose Interleukin-2 (IL-2) bolus therapy
  4. Everolimus (mTOR inhibitor) monotherapy

Explanation

For patients with previously untreated IMDC intermediate- or poor-risk advanced clear cell renal cell carcinoma, dual immune checkpoint blockade with ipilimumab plus nivolumab (CheckMate 214) or an IO-TKI combination (pembrolizumab + lenvatinib [CLEAR], nivolumab + cabozantinib [CheckMate 9ER], or pembrolizumab + axitinib [KEYNOTE-426]) represents the standard of care, demonstrating significant overall survival superiority over sunitinib monotherapy.

Question 26Solid tumors: site, stage, biology and treatment intent

A 52-year-old woman undergoes radical nephrectomy for a 9.5 cm clear cell renal cell carcinoma with renal vein invasion and macroscopic perinephric fat invasion (pT3a pN0 M0, Grade 3), representing a high risk of postoperative recurrence. According to the Phase III KEYNOTE-564 trial, what adjuvant therapy provides a statistically significant disease-free and overall survival benefit?

  1. Adjuvant Sunitinib for 1 year
  2. Adjuvant Sorafenib for 3 years
  3. Adjuvant Pembrolizumab (200 mg IV every 3 weeks or 400 mg IV every 6 weeks) for up to 1 year Correct answer.
  4. Observation with imaging surveillance alone

Explanation

The Phase III KEYNOTE-564 trial demonstrated that adjuvant pembrolizumab for approximately 1 year significantly improves disease-free survival (DFS) and overall survival (OS, HR 0.62) in patients with clear cell renal cell carcinoma at high risk of recurrence following radical or partial nephrectomy (or after complete metastasectomy). It is the first and only adjuvant therapy in RCC to demonstrate a proven overall survival advantage.

Question 27Solid tumors: site, stage, biology and treatment intent

A 67-year-old male with previously untreated, locally advanced unresectable urothelial carcinoma of the bladder presents with ECOG performance status 1 and normal organ function. Which systemic regimen demonstrated unprecedented doubling of median progression-free and overall survival compared to standard gemcitabine plus platinum chemotherapy in the Phase III EV-302 / KEYNOTE-A39 trial?

  1. Atezolizumab monotherapy
  2. Methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC)
  3. Docetaxel plus gemcitabine
  4. Enfortumab vedotin (ADC targeting Nectin-4) combined with Pembrolizumab Correct answer.

Explanation

The landmark Phase III EV-302 (KEYNOTE-A39) trial established the combination of Enfortumab vedotin (an antibody-drug conjugate targeting Nectin-4 carrying a monomethyl auristatin E payload) plus Pembrolizumab (anti-PD-1) as the new global first-line standard of care for locally advanced or metastatic urothelial carcinoma, nearly doubling median overall survival (31.5 vs 16.1 months, HR 0.47) compared to platinum-based chemotherapy.

Question 28Solid tumors: site, stage, biology and treatment intent

A 45-year-old man undergoes complete wide local excision and complete lymph node dissection for a clinical Stage IIIC cutaneous melanoma of the back with 3 positive regional lymph nodes (pT4b pN2a M0). Molecular analysis of the primary tumor confirms a BRAF p.V600E mutation. According to ESMO guidelines and landmark Phase III trials (COMBI-AD, CheckMate 238, KEYNOTE-054), what are the standard adjuvant systemic therapy options?

  1. 12 months of targeted therapy with Dabrafenib plus Trametinib OR 12 months of anti-PD-1 monotherapy with Pembrolizumab or Nivolumab Correct answer.
  2. High-dose interferon-alpha-2b for 12 months
  3. Ipilimumab 10 mg/kg monotherapy for 3 years
  4. Dacarbazine chemotherapy for 6 cycles

Explanation

For patients with completely resected Stage III BRAF V600-mutated cutaneous melanoma, standard adjuvant options with proven relapse-free survival benefits include 12 months of the oral targeted combination dabrafenib plus trametinib (COMBI-AD trial) or 12 months of anti-PD-1 checkpoint inhibition with pembrolizumab (KEYNOTE-054) or nivolumab (CheckMate 238).

Question 29Solid tumors: site, stage, biology and treatment intent

A 53-year-old woman with newly diagnosed FIGO Stage IIIC high-grade serous ovarian cancer undergoes primary debulking surgery to no macroscopic residual disease (R0). Somatic and germline genetic testing confirms a deleterious BRCA1 mutation. She completes 6 cycles of adjuvant carboplatin plus paclitaxel with a complete clinical and radiographic response (normal CA-125 and normal CT scans). Based on the SOLO-1 trial, what is the standard maintenance therapy?

  1. Bevacizumab monotherapy for 5 years
  2. Olaparib orally twice daily for up to 2 years Correct answer.
  3. Tamoxifen 20 mg daily for 5 years
  4. Intravenous paclitaxel maintenance monthly for 12 months

Explanation

In the Phase III SOLO-1 trial, maintenance therapy with the PARP inhibitor olaparib for 2 years in patients with newly diagnosed advanced BRCA-mutated ovarian cancer who attained a clinical response to first-line platinum-based chemotherapy resulted in an unprecedented sustained progression-free survival benefit (median PFS 56.0 vs 13.8 months) and a long-term overall survival advantage.

Question 30Solid tumors: site, stage, biology and treatment intent

A 62-year-old man is diagnosed with a locally advanced, unresectable gastrointestinal stromal tumor (GIST) of the gastric fundus. Molecular pathology reveals a PDGFRA exon 18 D842V point mutation. Which targeted tyrosine kinase inhibitor is specifically approved and highly effective for this mutation, which is intrinsically resistant to imatinib, sunitinib, and regorafenib?

  1. Ripretinib
  2. Cabozantinib
  3. Avapritinib Correct answer.
  4. Larotrectinib

Explanation

The PDGFRA exon 18 D842V mutation confers primary structural resistance to classical type II TKIs (imatinib, sunitinib, regorafenib) by shifting the kinase into an active conformation. Avapritinib is a potent, selective type I kinase inhibitor specifically engineered to target active-conformation KIT and PDGFRA D842V mutants. In the NAVIGATOR trial, avapritinib achieved an unprecedented 91% overall response rate in PDGFRA D842V-mutant GIST.

Question 31Systemic anticancer mechanisms and precision oncology

What is the key biological and pharmacological difference between anti-PD-1 monoclonal antibodies (e.g., Pembrolizumab, Nivolumab) and anti-PD-L1 monoclonal antibodies (e.g., Atezolizumab, Durvalumab)?

  1. Anti-PD-1 antibodies deplete regulatory T-cells via antibody-dependent cellular cytotoxicity (ADCC), whereas anti-PD-L1 antibodies do not
  2. Anti-PD-L1 antibodies cross the blood-brain barrier via active transport, while anti-PD-1 antibodies are strictly excluded from the CNS
  3. Anti-PD-1 antibodies irreversibly alkylate the PD-1 receptor, whereas anti-PD-L1 antibodies bind non-covalently
  4. Anti-PD-1 antibodies block PD-1 interactions with both PD-L1 and PD-L2 ligands, whereas anti-PD-L1 antibodies leave the PD-1 / PD-L2 interaction intact Correct answer.

Explanation

Programmed death-1 (PD-1) has two physiological ligands: PD-L1 (B7-H1) and PD-L2 (B7-DC). Anti-PD-1 antibodies bind directly to the PD-1 receptor on T cells, blocking engagement by both PD-L1 and PD-L2. In contrast, anti-PD-L1 antibodies selectively bind the PD-L1 ligand on tumor and antigen-presenting cells, preventing PD-L1/PD-1 and PD-L1/B7-1 binding while leaving the PD-1/PD-L2 inhibitory axis intact, which has been hypothesized to modulate pulmonary immune tolerance.

Question 32Systemic anticancer mechanisms and precision oncology

A 56-year-old patient with metastatic melanoma achieves a durable complete response to single-agent pembrolizumab for 2 years, but subsequently develops progressive subcutaneous and hepatic metastases. Biopsy of a progressing lesion reveals an acquired loss-of-function mutation in the Beta-2-microglobulin (B2M) gene. What is the precise molecular mechanism by which B2M loss mediates resistance to anti-PD-1 therapy?

  1. B2M loss prevents the cell-surface assembly and stable expression of Major Histocompatibility Complex (MHC) Class I molecules, preventing CD8+ cytotoxic T-cell recognition of tumor neoantigens Correct answer.
  2. B2M loss triggers overexpression of CTLA-4 on the tumor cell membrane
  3. B2M loss prevents intracellular phosphorylation of the EGFR tyrosine kinase domain
  4. B2M loss degrades circulating IgG4 monoclonal antibodies via the ubiquitin-proteasome pathway

Explanation

Beta-2-microglobulin (B2M) is an obligatory invariant light chain component required for the proper folding, cell-surface trafficking, and structural stability of all MHC Class I (HLA-A, HLA-B, HLA-C) molecules. Inactivating mutations or loss of heterozygosity in B2M abolishes MHC Class I surface expression, making tumor cells invisible to CD8+ cytotoxic T lymphocytes and causing acquired resistance to immune checkpoint blockade.

Question 33Systemic anticancer mechanisms and precision oncology

Within an explicitly selected iRECIST assessment in a clinically stable patient receiving checkpoint therapy, the scan meets initial progression criteria while the patient remains well enough for confirmation. Which listed classification and short-interval confirmation approach fits that framework?

  1. Immediately terminate immunotherapy, declare therapeutic failure, and transition to hospice care
  2. Immediately switch to salvage cytotoxic chemotherapy with dacarbazine
  3. Classify as unconfirmed progressive disease (iUPD), continue nivolumab, and obtain a mandatory confirmatory CT scan in 4 to 8 weeks Correct answer.
  4. Administer high-dose pulse corticosteroids to suppress tumor growth

Explanation

In immuno-oncology, 'pseudoprogression' refers to a transient increase in tumor burden or the appearance of new lesions caused by massive intratumoral infiltration of activated immune effector cells and edema, followed by subsequent tumor regression. Under iRECIST guidelines, an initial increase in tumor size in a clinically stable or improving patient is categorized as unconfirmed progressive disease (iUPD). The patient should continue immunotherapy and undergo confirmatory imaging 4–8 weeks later to distinguish pseudoprogression from true progression (iCPD).

Question 34Systemic anticancer mechanisms and precision oncology

Which design characteristic of Trastuzumab deruxtecan (T-DXd) explains its potent 'bystander antitumor effect' and high activity in tumors with heterogeneous or low HER2 expression?

  1. An uncleavable thioether linker that permanently traps the drug inside the primary target cell
  2. An auristatin payload that covalently binds to cell-surface CD30 receptors
  3. An anti-HER2 IgG3 backbone that activates the classical complement cascade exclusively
  4. A high drug-to-antibody ratio (~8:1), an enzymatically cleavable tetrapeptide linker, and a membrane-permeable topoisomerase I inhibitor payload Correct answer.

Explanation

Trastuzumab deruxtecan (T-DXd) incorporates several innovative engineering features: a high drug-to-antibody ratio (DAR ~8:1), a tumor-selective cleavable tetrapeptide linker (cleaved by lysosomal cathepsins upregulated in tumor cells), and a potent topoisomerase I inhibitor payload (deruxtecan / DXd). Crucially, the released DXd payload is highly lipophilic and membrane-permeable, allowing it to diffuse out of the antigen-positive cell into neighboring antigen-negative/low tumor cells to exert a potent 'bystander killing effect'.

Question 35Systemic anticancer mechanisms and precision oncology

What is the specific target antigen and cytotoxic payload of the antibody-drug conjugate Sacituzumab govitecan?

  1. Humanized anti-TROP-2 antibody linked to SN-38 (a topoisomerase I inhibitor) Correct answer.
  2. Anti-HER3 antibody linked to monomethyl auristatin E (MMAE)
  3. Anti-Nectin-4 antibody linked to calicheamicin
  4. Anti-CD22 antibody linked to DM1 (maytansinoid)

Explanation

Sacituzumab govitecan is an antibody-drug conjugate comprising a humanized monoclonal antibody directed against Trophoblast cell-surface antigen-2 (TROP-2)-a transmembrane glycoprotein overexpressed in many epithelial cancers-coupled via a hydrolyzable pH-sensitive linker to SN-38, the active metabolite of irinotecan (a potent topoisomerase I inhibitor), with a high drug-to-antibody ratio of 7.6:1.

Question 36Systemic anticancer mechanisms and precision oncology

Enfortumab vedotin is an antibody-drug conjugate approved for advanced urothelial carcinoma. What is the cell-surface adhesion molecule it targets, and what is its cytotoxic payload mechanism?

  1. Targets Claudin-6 and causes DNA double-strand crosslinking via platinum adducts
  2. Targets Nectin-4 and delivers monomethyl auristatin E (MMAE), which inhibits tubulin polymerization and disrupts microtubules Correct answer.
  3. Targets EpCAM and delivers radioactive bismuth-213 to induce alpha-particle ionization
  4. Targets PSMA and delivers a topoisomerase II inhibitor

Explanation

Enfortumab vedotin targets Nectin-4, an intercellular adhesion molecule belonging to the nectin family that is highly expressed in urothelial carcinomas. Upon binding and internalization, the cleavable linker releases monomethyl auristatin E (MMAE), a synthetic antineoplastic agent that binds to tubulin and inhibits microtubule polymerization, arresting the cell cycle in G2/M phase and triggering apoptotic cell death.

Question 37Systemic anticancer mechanisms and precision oncology

What is the biological principle of 'Synthetic Lethality' as exploited by Poly(ADP-ribose) polymerase (PARP) inhibitors in oncology?

  1. Simultaneous inhibition of VEGF and EGFR receptors to induce endothelial apoptosis
  2. Co-administration of two cytotoxic agents that cross the blood-brain barrier synergistically
  3. A condition where a defect in either of two DNA repair pathways (e.g., base excision repair via PARP or homologous recombination via BRCA1/2) is compatible with cell viability, but simultaneous disruption of both pathways causes selective tumor cell death Correct answer.
  4. Activation of the complement cascade by dual monoclonal antibody binding

Explanation

Synthetic lethality occurs when a mutation or deficiency in either of two genes/pathways alone is non-lethal, but the combination of both defects leads to cell death. In tumors harboring homologous recombination deficiency (HRD, such as BRCA1/2 loss), inhibition and trapping of PARP1 prevents the repair of single-strand DNA breaks via base excision repair. During replication, these unrepaired breaks collapse replication forks into lethal double-strand breaks, which cannot be repaired accurately by non-functional homologous recombination, resulting in selective tumor cell apoptosis while sparing normal cells.

Question 38Systemic anticancer mechanisms and precision oncology

Which listed acquired change can restore functional homologous-recombination repair and contribute to resistance to PARP inhibitors or platinum treatment in a BRCA-mutated tumor?

  1. Overexpression of thymidylate synthase
  2. Upregulation of the multi-drug resistance transporter P-glycoprotein exclusively
  3. Constitutive activation of the androgen receptor splice variant AR-V7
  4. Secondary 'reversion mutations' in BRCA1 or BRCA2 that restore the open reading frame and functional homologous recombination repair Correct answer.

Explanation

The primary mechanism of acquired clinical resistance to PARP inhibitors and platinum agents in BRCA1/2-mutated cancers is the development of secondary somatic 'reversion mutations' (insertions, deletions, or point mutations). These secondary mutations restore the functional open reading frame of the mutated BRCA gene, reinstating homologous recombination proficiency and rendering the tumor cell resistant to PARP trapping and DNA crosslinking.

Question 39Systemic anticancer mechanisms and precision oncology

A progressing EGFR-mutated lung tumor has acquired C797S during osimertinib treatment. Which listed molecular mechanism explains how this change can impair binding of an irreversible third-generation EGFR inhibitor?

  1. C797S replaces the nucleophilic cysteine residue in the ATP-binding pocket with serine, preventing covalent bonding of irreversible third-generation TKIs Correct answer.
  2. C797S causes rapid lysosomal degradation of the EGFR receptor protein
  3. C797S prevents dimerization of EGFR with HER2 receptors
  4. C797S converts the receptor into an insulin-like growth factor receptor

Explanation

Osimertinib is an irreversible, third-generation EGFR TKI that achieves potent kinase inhibition by forming a covalent bond with the conserved cysteine residue at position 797 (C797) in the ATP-binding cleft of the EGFR kinase domain. Mutation of this cysteine to serine (C797S) eliminates the nucleophilic sulfhydryl group, abolishing covalent drug binding and causing high-level resistance to osimertinib.

Question 40Systemic anticancer mechanisms and precision oncology

Why does monotherapy with a selective BRAF inhibitor (such as Vemurafenib or Dabrafenib) cause paradoxical activation of the MAPK pathway in cells with wild-type BRAF or upstream RAS mutations, frequently inducing cutaneous squamous cell carcinomas or keratoacanthomas?

  1. BRAF inhibitors directly bind to and phosphorylate nuclear retinoblastoma protein
  2. In the presence of active RAS-GTP, BRAF inhibitors promote the formation of CRAF-BRAF or CRAF-CRAF dimers where drug binding to one monomer transactivates the uninhibited monomer Correct answer.
  3. BRAF inhibitors upregulate vascular endothelial growth factor receptor 2 (VEGFR-2)
  4. BRAF inhibitors act as alkylating agents that directly mutate the TP53 tumor suppressor gene

Explanation

In cells with wild-type BRAF or upstream RAS mutations, selective BRAF inhibitors induce conformational changes that promote RAF dimerization (BRAF-CRAF or CRAF-CRAF). Binding of the inhibitor to one protomer causes allosteric transactivation of the adjacent uninhibited protomer, paradoxically hyperactivating downstream MEK and ERK phosphorylation. This promotes hyperproliferation of pre-malignant keratinocytes harboring HRAS mutations. Adding a MEK inhibitor (e.g., trametinib) blocks this downstream activation, preventing paradoxical skin tumors.

Question 41Systemic anticancer mechanisms and precision oncology

A 52-year-old non-smoker with metastatic NSCLC has a confirmed KIF5B-RET gene rearrangement on RNA sequencing. Staging brain MRI shows two asymptomatic 5 mm cerebral metastases. Which selective RET kinase inhibitor has demonstrated high systemic response rates and robust intracranial efficacy in the Phase III LIBRETTO-431 and Phase I/II LIBRETTO-001 trials?

  1. Vandetanib
  2. Cabozantinib
  3. Alectinib
  4. Selpercatinib (or Pralsetinib) Correct answer.

Explanation

Selpercatinib and pralsetinib are potent, highly selective RET kinase inhibitors specifically designed to inhibit wild-type and mutated/rearranged RET while sparing VEGFR-2 and other off-target kinases. In the LIBRETTO and ARROW trials, selpercatinib and pralsetinib demonstrated marked superiority in response rate, progression-free survival, and CNS penetration (>80% intracranial response rate) compared to multi-kinase inhibitors (cabozantinib, vandetanib) or chemotherapy.

Question 42Systemic anticancer mechanisms and precision oncology

What are the primary molecular mechanisms of cytotoxicity and myocardial injury associated with anthracyclines (such as Doxorubicin and Epirubicin)?

  1. Topoisomerase II-alpha inhibition (stabilizing cleavable DNA complexes) and Topoisomerase II-beta inhibition in cardiomyocytes, accompanied by iron-dependent generation of reactive oxygen species (ROS) Correct answer.
  2. Selective inhibition of the 26S proteasome inducing accumulation of misfolded proteins
  3. Irreversible inhibition of ribonucleotide reductase depleting cellular dNTP pools
  4. Binding to the colchicine site on tubulin preventing mitotic spindle formation

Explanation

Anthracyclines exert their primary antitumor cytotoxicity by intercalating into DNA and inhibiting Topoisomerase II-alpha, creating persistent double-strand DNA breaks that trigger apoptosis. Their cardiotoxicity is mediated primarily by inhibition of Topoisomerase II-beta in non-dividing cardiomyocytes (leading to mitochondrial dysfunction and cell death) and the iron-dependent generation of free radicals (reactive oxygen species) that cause lipid peroxidation of the cardiomyocyte membrane.

Question 43Systemic anticancer mechanisms and precision oncology

How do Taxanes (Paclitaxel, Docetaxel) differ mechanistically from Vinca Alkaloids (Vincristine, Vinblastine) with respect to microtubule dynamics?

  1. Taxanes inhibit microtubule polymerization by binding tubulin heterodimers, whereas vinca alkaloids stabilize microtubules
  2. Taxanes hyper-stabilize microtubules by binding the beta-tubulin subunit and preventing depolymerization, whereas vinca alkaloids bind tubulin dimers to inhibit microtubule assembly and promote depolymerization Correct answer.
  3. Taxanes cleave the mitotic spindle via endonuclease activation, whereas vinca alkaloids inhibit topoisomerase I
  4. Taxanes act solely in the S phase of the cell cycle, whereas vinca alkaloids act exclusively in G1

Explanation

Both drug classes are antimitotic spindle poisons acting during M phase, but they have opposing mechanisms: Taxanes bind to the interior surface of the beta-tubulin subunit, promoting microtubule assembly and preventing depolymerization (freezing the spindle), whereas Vinca alkaloids bind to the beta-tubulin subunit at the interface between heterodimers, preventing tubulin polymerization and causing microtubule disassembly.

Question 44Systemic anticancer mechanisms and precision oncology

What is the primary mechanism of action of Platinum-based chemotherapeutic agents (Cisplatin, Carboplatin, Oxaliplatin)?

  1. Inhibition of dihydrofolate reductase preventing purine biosynthesis
  2. Direct degradation of the cellular nuclear envelope via lipid peroxidation
  3. Formation of covalent intrastrand (predominantly 1,2-intrastrand d(GpG) and d(ApG)) and interstrand DNA crosslinks at the N7 position of purines, bending the DNA helix and triggering apoptosis Correct answer.
  4. Inhibition of vascular endothelial growth factor receptor tyrosine kinases

Explanation

Platinum compounds undergo intracellular aquation (chloride or carboxylate leaving group displaced by water) to form reactive electrophilic species. These bind covalently to the N7 position of purine bases (predominantly guanine), forming 1,2-intrastrand (90%) and interstrand (5–10%) DNA crosslinks. This distorts the DNA double helix, blocks replication forks and RNA polymerase transcription, and activates apoptosis via p53 and mismatch repair recognition pathways.

Question 45Systemic anticancer mechanisms and precision oncology

What is the biochemical rationale for administering Leucovorin (folinic acid) in combination with 5-Fluorouracil (5-FU) in gastrointestinal chemotherapy regimens (e.g., FOLFOX, FOLFIRI)?

  1. Leucovorin protects normal mucosal cells by actively displacing 5-FU from the cellular membrane
  2. Leucovorin accelerates the hepatic enzymatic clearance of toxic 5-FU catabolites
  3. Leucovorin inhibits the P-glycoprotein efflux pump, increasing intracellular 5-FU absorption
  4. Leucovorin provides an excess pool of 5,10-methylenetetrahydrofolate, forming a stable ternary complex with thymidylate synthase and FdUMP, thereby enhancing TS inhibition Correct answer.

Explanation

5-Fluorouracil is converted intracellularly to 5-fluoro-2'-deoxyuridine-5'-monophosphate (FdUMP), which inhibits thymidylate synthase (TS). Leucovorin (folinic acid) is converted to 5,10-methylenetetrahydrofolate, which acts as a cofactor to form a tight, stable covalent ternary complex with TS and FdUMP. This prevents the normal dissociation of FdUMP from TS, dramatically prolonging enzyme inhibition and enhancing the cytotoxic efficacy of 5-FU.

Question 46Systemic anticancer mechanisms and precision oncology

Under the named European pretreatment-safety recommendation for systemic fluorouracil, capecitabine or tegafur, which listed deficiency assessment helps identify risk of severe fluoropyrimidine toxicity?

  1. Testing for Dihydropyrimidine Dehydrogenase (DPYD) deficiency via genotyping for validated allelic variants (*2A, *13, c.2846A>T, HapB3) or phenotypic measurement of plasma uracil concentration Correct answer.
  2. Testing for CYP2D6 poor-metabolizer status
  3. Testing for HLA-B*5701 hypersensitivity allele
  4. Screening for G6PD deficiency via spectrophotometric assay

Explanation

Dihydropyrimidine dehydrogenase (DPD, encoded by the DPYD gene) is the rate-limiting enzyme responsible for catabolizing >80% of administered 5-FU into inactive dihydrofluorouracil. Patients with complete or partial DPD deficiency accumulate massive toxic concentrations of active fluoropyrimidines, leading to severe pancytopenia, mucositis, intractable diarrhea, neurotoxicity, and high mortality. Routine pre-treatment screening via DPYD genotyping (*2A, *13, c.2846A>T, HapB3/c.1129-5923C>G) and/or uracil phenotyping is mandatory in Europe to guide dose reductions or drug avoidance.

Question 47Systemic anticancer mechanisms and precision oncology

A patient with metastatic colorectal cancer is scheduled to receive high-dose Irinotecan. Genetic testing reveals that the patient is homozygous for the UGT1A1*28 allele (7/7 TA repeats in the promoter region). What is the major clinical consequence of this genetic variant?

  1. Complete resistance to irinotecan due to inability to convert irinotecan to SN-38
  2. Impaired hepatic glucuronidation of the active toxic metabolite SN-38, resulting in substantially increased risk of severe (Grade 3/4) neutropenia and diarrhea Correct answer.
  3. Accelerated renal clearance of irinotecan requiring a 200% dose increase
  4. Immediate IgE-mediated anaphylaxis upon initial drug infusion

Explanation

Irinotecan is a prodrug converted by carboxylesterases into SN-38, an active topoisomerase I inhibitor that is 1000-fold more potent. SN-38 is cleared primarily through hepatic glucuronidation to inactive SN-38G by the enzyme UDP-glucuronosyltransferase 1A1 (UGT1A1). Homozygosity for the UGT1A1*28 polymorphism (associated with Gilbert syndrome) reduces UGT1A1 expression and enzyme activity by ~70%, leading to delayed SN-38 clearance, high systemic exposure, and severe life-threatening neutropenia and secretory diarrhea, necessitating pre-emptive irinotecan dose reduction.

Question 48Systemic anticancer mechanisms and precision oncology

Why are the lungs and skin uniquely vulnerable to Bleomycin toxicity (such as pulmonary fibrosis and hyperpigmentation/flagellate erythema)?

  1. Bleomycin selectively binds to pulmonary surfactant and epidermal keratinocytes
  2. Pulmonary and cutaneous endothelial cells overexpress P-glycoprotein efflux pumps
  3. Bleomycin is actively concentrated inside alveolar macrophages via folate receptors
  4. Lung and skin tissues have exceptionally low levels of the inactivating enzyme Bleomycin Hydrolase, leading to unchecked drug accumulation and iron-mediated ROS generation Correct answer.

Explanation

Bleomycin is normally degraded and inactivated in most somatic tissues by the cytosolic enzyme bleomycin hydrolase (an aminopeptidase). However, lung tissue and skin possess very low endogenous levels of bleomycin hydrolase. Consequently, intact bleomycin accumulates in high concentrations in the lungs and dermis, chelates intracellular Fe(II), and binds oxygen to generate sustained reactive oxygen species that cause DNA strand breaks, alveolar epithelial injury, and progressive pulmonary fibrosis.

Question 49Systemic anticancer mechanisms and precision oncology

What are the canonical class-specific toxicities associated with anti-angiogenic monoclonal antibodies targeting VEGF signaling (e.g., Bevacizumab, Ramucirumab)?

  1. Arterial hypertension, proteinuria, arterial thromboembolism, impaired surgical wound healing, and gastrointestinal perforation Correct answer.
  2. Pulmonary fibrosis, hemolytic uremic syndrome, and cerebellar ataxia
  3. Immune-related hypophysitis, vitiligo, and autoimmune thyroiditis
  4. Peripheral sensory neuropathy, alopecia, and acute hemorrhagic cystitis

Explanation

Inhibition of the vascular endothelial growth factor (VEGF) pathway disrupts normal endothelial cell survival, nitric oxide production, and fenestration maintenance. Classic class toxicities include arterial hypertension (due to decreased endothelial nitric oxide), proteinuria and renal glomerular injury (thrombotic microangiopathy), arterial thromboembolic events (stroke, myocardial infarction), delayed wound healing (warranting 4–6 week surgical washout periods), and life-threatening gastrointestinal perforation.

Question 50Systemic anticancer mechanisms and precision oncology

Which clinical application of cell-free circulating tumor DNA (ctDNA) analysis via 'liquid biopsy' has been established as a valid tool in modern precision breast oncology?

  1. Replacing histologic core needle biopsy for initial tumor grade and primary diagnostic confirmation
  2. Detecting acquired ESR1 ligand-binding domain mutations in ER-positive metastatic breast cancer to guide the switch to oral selective estrogen receptor degraders (e.g., Elacestrant) Correct answer.
  3. Determining patient eligibility for adjuvant trastuzumab in HER2-negative tumors
  4. Replacing routine mammography screening in average-risk women

Explanation

In ER-positive, HER2-negative metastatic breast cancer previously treated with aromatase inhibitors and CDK4/6 inhibitors, liquid biopsy ctDNA testing reliably detects emergent ESR1 missense mutations (such as Y537S, D538G) that cause constitutive, ligand-independent estrogen receptor activation. In the Phase III EMERALD trial, identifying ctDNA ESR1 mutations guided successful treatment with elacestrant, a novel oral SERD that significantly prolonged progression-free survival over standard endocrine monotherapy.